FDA approves AstraZeneca breast cancer drug; biotech funding round highlights

FDA approval of an AstraZeneca breast cancer drug marks a regulatory milestone, though details on the specific drug and indication are limited. The item also notes Roivant's mid-stage results and Moonwalk's funding for obesity drugs, indicating continued biotech sector activity. Market impact is sector-specific, with no clear macro-directional signal.